{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464206452
| IUPAC_name = (4''R'')-3-(5-oxo-<small>L</small>-prolyl)-1,3-thiazolidine-4-carboxylic acid
| image = Pidotimod.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|pidotimod}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number =  
| ATC_prefix = L03
| ATC_suffix = AX05
| PubChem = 65944
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 59348
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 785363R681
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07261
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1488165

<!--Chemical data-->
| C=9 | H=12 | N=2 | O=4 | S=1 
| molecular_weight = 244.26758 g/mol
| smiles = O=C(O)[C@H]2N(C(=O)[C@H]1NC(=O)CC1)CSC2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C9H12N2O4S/c12-7-2-1-5(10-7)8(13)11-4-16-3-6(11)9(14)15/h5-6H,1-4H2,(H,10,12)(H,14,15)/t5-,6-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UUTKICFRNVKFRG-WDSKDSINSA-N
| synonyms = <small>(4''R'')-3-[(2''S'')-5-oxopyrrolidine-2-carbonyl]-1,3-thiazolidine-4-carboxylic acid</small>
}}
'''Pidotimod''' is an [[immunostimulant]].<ref name="pmid18806958">{{cite journal |vauthors=Du XF, Jiang CZ, Wu CF, Won EK, Choung SY |title=Synergistic immunostimulating activity of pidotimod and red ginseng acidic polysaccharide against cyclophosphamide-induced immunosuppression |journal=Archives of pharmacal research |volume=31 |issue=9 |pages=1153â€“9 |date=September 2008 |pmid=18806958 |doi=10.1007/s12272-001-1282-6}}</ref>

==References==
{{Reflist}}

{{Immunostimulants}}

[[Category:Carboxylic acids]]
[[Category:Immunostimulants]]
[[Category:Thiazolidines]]
[[Category:Carboxamides]]
[[Category:Pyrrolidines]]
[[Category:Lactams]]


{{antineoplastic-drug-stub}}